I can't tell if this is bad for the big labs, or good because it means they now have an excuse for not showing meaningful progress in the lead ups to their IPOs.

What would that IPO look like when they can’t sell their product to users and are hard capped on how much money they can earn?

It will reduce usage and spur investments into competitors from the EU and likely other large nations, most likely hurting these upcoming IPOs.